TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Caregiver Needs Questionnaire (CNF)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: baPWV (brachial-ankle Pulse Wave Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of PICCs malposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute post-operative complications averted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in fecal microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Outcome of Bladder Wound, Rectum Wound, Abnormal Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of tubal cause of infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in thickness of the quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in quality of the quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: C0 of tacrolimus after the initial dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of out-of-range C0 after initial dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of dose adjustments made to achieve therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of participants with adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral binding of [123I]FP-CIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean age of onset of type 1 and type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of diabetes in type 1 and type 2 diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of diabetic patients with HbA1c target below 7.0% and below 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycated hemoglobin (Hemoglobin A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GOSE
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With a Decrease in Threshold Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to reach peak plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of elastase, Protease 3 and cathepsine G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dieting Behavior and Restraint
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Body Dissatisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motor and Strength Outcome Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate variability (time-domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart rate variability (frequency-domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Physical Examination Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Abnormal Vital Sign Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of cytochrome P450 cholesterol 27-hydroxylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in muscle myostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FHL-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amplitude of the gustatory evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of the gustatory evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial expression recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triacylglycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative cognitive deficit (POCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Size of calculi at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of calculi at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lithiasic activity at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Surface Refractive Index Shifts at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Refractive Index Shifts at 10 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Refractive Index Shifts at 15 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pCRB (pathological complete response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the levels of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in the levels of Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Any Hospital Readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hamilton Depression Rating Scale (HDRS21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Swiss Spinal Stenosis Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Ambulation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time to First Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Sensory Nerve Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in urinary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum keratometry (Kmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from the time of dosing to the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal elimination half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Progression Free Survival (PFS) Time
Endpoint domain: Mortality/survival
Primary endpoint: Growth Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear Growth Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of documented monomorphic ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Any Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Solicited General AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Extubation outcome (success or failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of common cold symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superiority of norursodeoxycholic acid (norUDCA) compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resectability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects and adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of positive urine leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in postoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of total intraoperative remifentanil infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with reported deaths from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Solicited Injection-Site Reactions Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited Systemic Reactions Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: change in haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients discontinuing prematurely from study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lipid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraoperative and short term postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Long term febrile malaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Very Low Density Lipoprotein-Triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoB-100 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Essential Tremor Rating Assessment Scale (TETRAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Burke-Fahn-Marsden (BFM) Dystonia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Yale Global Tic Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful intratracheal tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Favorable neurological performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change-From-Baseline QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in salivary SOD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in reactive hyperemia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between TSK and ACL-RSI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between clinical and psychological features
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Association between clinical features and level of stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with orgasm dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Device and/or System Related Complication (DSRC)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Pressure Sensor Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Failure Hospitalization (HFH) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Anterolateral territory graft patency index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in skills and confidence in conducting parent consultations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distinguishing healthy and tumoral specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Hypogonadism in Participants Based on Serum Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in mitochondria respiration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skeletal muscle single fibre force (in micro Newtons)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Neurological outcomes - nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neurological outcomes - fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neurological outcomes - neurocognitive assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Negative Urinary Drug Screens for Cannabis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in migraine attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in migraine attack-related functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Caregiver's impression of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor response pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes Per Week of Moderate-to-Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical activity of the diaphragm (Edi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of AZD1775 based on incidence of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of DAA-I
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical defecation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in FibroScan® score (kPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of patients with medication discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Epidural Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Needle Passes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or other vascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Efficacy of crizotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of AZD5122 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Baseline and Peak TNF-alpha Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined rate of stroke and death
Endpoint domain: Mortality/survival
Primary endpoint: Nasofibroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Voice control and recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edmonton Symptom Assessment System - Revised
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aortic VTI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of intraoperative hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Technical Success of implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of Naftin® 1% Cream
Endpoint domain: Adverse events/effects
Primary endpoint: Pain relief measured in the Kujala score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of sickness absence days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma levels of casopitant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of D-lactic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Concentration of Diamine Oxidase (DAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative Exhaust Time
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Days to Return to Full Unrestricted Athletic Participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: En bloc resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of status of proctologic surgical and outpatient activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success rate of patient derived tumor cell model establishment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pCLE compared to conventional forceps biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Response (CR) after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of emergency visits needing surgical consult
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The ratio of severe presentations to non-severe presentations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of best spectacle corrected acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended dose for phase II study
Endpoint domain: Resource use
Primary endpoint: Percentage of Participants With a CR or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participants with anti-diphtheria antibody concentrations ≥ 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with anti-tetanus antibody concentrations ≥ 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with a booster response for antibodies to Pertussis Toxoid (PT), Filamentous hemagglutinin (FHA), pertactin (PRN), Fimbriae types 2 and 3 (FIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postthrombotic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Hospital Stay After Surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Efficacy of desensitization protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of overt nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum level of tumor necrosis factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum level of interleukin-1 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes